Pfizer (NYSE:PFE) Trading Down 0.5%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s stock price traded down 0.5% on Friday . The stock traded as low as $27.99 and last traded at $28.04. 7,027,748 shares were traded during trading, a decline of 84% from the average session volume of 43,183,082 shares. The stock had previously closed at $28.18.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, May 2nd. BMO Capital Markets restated an "outperform" rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a research report on Friday, February 23rd. They issued a "buy" rating and a $36.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $36.00.

Pfizer Stock Down 0.6 %

The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market capitalization of $158.64 billion, a PE ratio of -466.26, a PEG ratio of 1.17 and a beta of 0.63. The business has a 50 day moving average of $26.97 and a two-hundred day moving average of $28.12.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts' expectations of $13.87 billion. Pfizer had a positive return on equity of 8.58% and a negative net margin of 0.56%. The firm's quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 EPS. Analysts predict that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer's dividend payout ratio (DPR) is presently -2,799.53%.

Institutional Investors Weigh In On Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clifford Swan Investment Counsel LLC raised its stake in shares of Pfizer by 4.7% in the fourth quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company's stock worth $12,007,000 after purchasing an additional 18,611 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new stake in Pfizer during the fourth quarter worth about $255,000. KLCM Advisors Inc. grew its holdings in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company's stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. Finally, Farmers Trust Co. grew its holdings in Pfizer by 2.0% during the fourth quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company's stock worth $6,503,000 after acquiring an additional 4,410 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.